Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.48 |
| ▸ | NOS1 | P29475 | 1/20 | 0.48 |
| ▸ | NOS2 | P35228 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | PIEZO1 | Q92508 | 1/20 | 0.39 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.38 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7804289 | 0.83 | POLQ (0.47) | NOS3NOS1NOS2HTTCYP3A4 | |
| SCHEMBL951751 | 0.82 | NOS3 (0.47) | NOS3NOS1NOS2HTTCYP3A4 | |
| SCHEMBL1125472 | 0.82 | NOS3 (0.47) | NOS3NOS1NOS2HTTCYP3A4 | |
| SCHEMBL18908921 | 0.82 | NOS3 (0.47) | NOS3NOS1NOS2HTTCYP3A4 | |
| SCHEMBL10283739 | 0.82 | NOS3 (0.50) | NOS3NOS1NOS2HTTCYP3A4 | |
| SCHEMBL147107 | 0.82 | NOS3 (0.47) | NOS3NOS1NOS2HTTCYP3A4 | |
| SCHEMBL1196343 | 0.82 | NOS3 (0.47) | NOS3NOS1NOS2HTTCYP3A4 | |
| Hydrochloric Acid SCHEMBL4496671 | 0.80 | NOS3 (0.46) | NOS3NOS1NOS2HTTCYP3A4 | |
| SCHEMBL3188993 | 0.79 | CES2 (0.46) | CYP3A4PIEZO1IDO1POLQCYP2D6 | |
| SCHEMBL938117 | 0.79 | IDO1 (0.46) | IDO1P2RX7SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3042895-A1 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2016-07-13 | — | — | EP | disclosed |
| EP-2316827-B1 | Piperazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC (CA) | 2016-01-27 | — | — | EP | disclosed |
| CN-102600162-A | Pyridazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC | 2012-07-25 | — | — | CN | disclosed |
| EP-1648874-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2011-10-05 | — | — | EP | disclosed |
| US-7964591-B2 | Pyridazine derivatives and their use as therapeutic agents | NOVARTIS PHARMA AG (CH) | 2011-06-21 | — | — | US | disclosed |
| EP-2316827-A1 | Piperazine derivatives and their use as therapeutic agents | Xenon Pharmaceuticals Inc. (CA) | 2011-05-04 | — | — | EP | disclosed |
| CN-101980709-A | Pyridazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC | 2011-02-23 | — | — | CN | disclosed |
| US-20110021530-A1 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS IN THE TREATMENT OF SKIN DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2011-01-27 | — | — | US | disclosed |
| US-20100311763-A1 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | NOVARTIS PHARMA AG (US) | 2010-12-09 | — | — | US | disclosed |
| EP-2257291-A2 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS IN THE TREATMENT OF SKIN DISORDERS | Xenon Pharmaceuticals Inc. (CA) | 2010-12-08 | — | — | EP | disclosed |
| US-20080280916-A1 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2008-11-13 | — | — | US | disclosed |
| CN-101160289-A | Pyridazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC (CA) | 2008-04-09 | — | — | CN | disclosed |
| US-7335658-B2 | Pyridazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2008-02-26 | — | — | US | disclosed |
| EP-1851205-A2 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2007-11-07 | — | — | EP | disclosed |
| CN-1829698-A | Pyridazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC (CA) | 2006-09-06 | — | — | CN | disclosed |
| WO-2006086447-A2 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-08-17 | — | — | WO | disclosed |
| EP-1648874-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-04-26 | — | — | EP | disclosed |
| US-20060009459-A1 | Pyridazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2006-01-12 | — | — | US | disclosed |
| US-20050065143-A1 | Pyridazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2005-03-24 | — | — | US | disclosed |
| WO-2005011655-A2 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065143-A1 | Pyridazine derivatives and their use as therapeutic agents | PRDX5, SNRPD3, SNRPD2 | NOS3 2048/4885NOS1 2627/4885NOS2 2379/4885 |
| US-20110021530-A1 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS IN THE TREATMENT OF SKIN DISORDERS | PRXL2A, CUTA, MC1R | NOS3 1827/4885NOS1 1941/4885NOS2 1887/4885 |
| US-20080280916-A1 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MC1R, CASP9, PRDX5 | NOS3 2708/4885NOS1 2964/4885NOS2 2895/4885 |
| US-20100311763-A1 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MC1R, CASP9, PRDX5 | NOS3 2708/4885NOS1 2964/4885NOS2 2895/4885 |
| US-20060009459-A1 | Pyridazine derivatives and their use as therapeutic agents | PRDX5, SNRPD3, C3AR1 | NOS3 2028/4885NOS1 2632/4885NOS2 2263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.